Methohexital

Summary

Methohexital (CHEMBL7413) is an approved small-molecule intravenous anaesthetic (ATC N01AF01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N01AF01 (+1 more)
• Clinical trials: 9
• Chemistry: 262.3 Da · C14H18N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL7413
Name	Methohexital
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9034
ChEBI	CHEBI:102216
ATC	N01AF01, N05CA15
Molecular formula	C14H18N2O3
Molecular weight	262.3
InChIKey	NZXKDOXHBHYTKP-UHFFFAOYSA-N

SMILES: CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C

IUPAC name: 5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione

ChEBI definition: A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.

Pharmacological roles (ChEBI): intravenous anaesthetic, drug allergen.

Also known as: Methohexital, Methohexital civ, Metohexital, methohexital, METHOHEXITAL

Parent form; salt/anhydrous children: CHEMBL30219

Patent coverage: 2,052 distinct patent families (8,340 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
Not specified	5
PHASE4	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05655754	PHASE4	RECRUITING	Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT
NCT01881763	PHASE4	COMPLETED	Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression
NCT04187196	PHASE4	COMPLETED	Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
NCT04022226	EARLY_PHASE1	COMPLETED	EEG Characteristics in ECT
NCT01309581	Not specified	TERMINATED	Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression
NCT01367119	Not specified	COMPLETED	Ketamine Anesthesia in Electroconvulsive Therapy
NCT01567852	Not specified	COMPLETED	Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time
NCT02624050	Not specified	COMPLETED	Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs
NCT02752724	Not specified	COMPLETED	Ketamine Anesthesia for Improvement of Depression in ECT

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).